I have a couple of quick points that I hope with make this more understandable. It's complex.
One of the problems in South Africa is that over 80% of people have had COVID. They do not see the value of having the vaccine, even though we know that in having had COVID, particularly omicron, you are not protected should we get another variant that looks like delta. Having had COVID, you still need to be immunized with at least one dose, and preferably two. That's number one. They're having trouble doing that.
Number two is that their population demographics are very different from our population demographics. Almost 50% of their population is under the age of 20. They did not see the mortality that we saw, because they don't have those people. I do a lot of work in sub-Saharan Africa in the other thing that I do with an organization called MicroResearch.
I know, from working with those countries, that it's different. Their diseases are different. Their health care system is not a system in many places. The other problem is that when the vaccines arrived, all too often they had very short expiry dates, so they had to give them to anybody who showed up. They were not able to follow the recommendations to give them to the highest risk people, where you were going to see the most benefit.
Because of that, the general public did not see the benefit. We saw that benefit in Canada. We saw how it decreased mortality. But they didn't get to do that.
I can add the other caveat, which is why your question is really important. We do know—and this is not being negative about sub-Saharan Africa—that because they had so much COVID disease going on, mutation was really easy. They had a lot of people who shed virus for a long period of time, because they had untreated, undiagnosed HIV.
In fact, some people said one thing we really need to do in sub-Saharan Africa is increase HIV diagnosis and treatment, so we will have less shedding of the COVID virus and less opportunity for it to mutate. That would benefit all of us.